FIRDAPSE IS THE ONLY FDA-APPROVED TREATMENT FOR PEDIATRIC PATIENTS (6 YEARS OF AGE AND OLDER)2,6

Dosing for pediatric patients ≥6 years of age2*

FIRDAPSE Pediatric Dosing Table
People icon

Review general FIRDAPSE dosing information here.

* In patients with renal or hepatic impairment and individuals known to be poor metabolizers of N-acetyltransferase 2 (NAT2), the starting dosage of FIRDAPSE should be the lowest recommended dose taken orally in divided doses. This dose should continue to be titrated to clinical effect and tolerability.2 Safety of FIRDAPSE was evaluated in pediatric patients in an expanded access program in which 21 pediatric patients received FIRDAPSE for at least 1 year. Adverse reactions reported in pediatric patients were similar to those seen in adult patients, with the exception of clinically significant weight loss in two pediatric patients at doses of 60 mg per day and higher.2

Help your patients reach their optimal therapeutic dose

Titration is an important step for new patients who are just getting started on FIRDAPSE and have not taken amifampridine before. By guiding your patients through the titration process, you can help:

  • Determine their optimal therapeutic dose of FIRDAPSE
  • Maximize neuromuscular benefit
  • Minimize issues with tolerability, including paresthesia
Suspension icon

FOR FIRDAPSE PATIENTS WITH SPECIAL DOSING OR ADMINISTRATION NEEDS

A suspension can be prepared for patients who: have dosing adjustments <5 mg, have trouble swallowing tablets, or require a feeding tube. Please refer to the Medication Guide.